Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC/CIK Immunotherapy + Chemotherapy in TNBC
NCT02539017Phase 2Withdrawn
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Nov 2015
- Primary completion
- Sep 2017
- Modality
- Whole Cell Cancer Vaccines, Allogeneic CAR-T, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor mRNA-transfected dendritic cell vaccine (Oslo University Hospital), unmodified CIK in triple-negative breast cancer (TNBC), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Planned start Nov 2015; status: withdrawn.
02
Drugs
autologous tumor mRNA-transfected dendritic cell vaccine (Oslo University Hospital)unmodified CIK
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02539017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02539017.